Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Current guidelines recommend the addition of proton pump inhibitors (PPI) to patients taking double anti-platelet therapy (Aspirin and Clopidogrel) to prevent upper GI bleeding1. Many post percutaneous coronary intervention (PCI) patients are treated with dual anti-platelet medications as well as PPI to prevent upper GI bleeding.
Recently, it was shown that PPI interact with the P450 system in the liver and reduce the platelet inhibitory effect of Clopidogrel2,3. Clopidogrel is activated by CYP2C19, which also metabolizes PPI4. Furthermore, a recent article showed increased mortality in patients taking PPI and clopidogrel compared with patients taking clopidogrel without PPI protection5. The degree of reduction in the platelet inhibitory properties of clopidogrel might vary among the different PPI4.
The use of PPI for GI protection in patients treated with dual anti-platelet therapy is not based on randomized trials, but rather on expert opinion. Since H2 blockers are also effective in preventing acid secretion and are not known to interact with the P450 system that affects clopidogrel, the investigators hypothesized that these group of drugs will not interfere with the positive antiplatelet effects of clopidogrel and therefore will offer a good alternative treatment option.
| Condition | Intervention | Phase |
|---|---|---|
|
Coronary Heart Disease GI Bleeding |
Drug: PPI Platelet Inhibitory |
Phase 4 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Pharmacokinetics/Dynamics Study Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Platelet Inhibitory Effect of Clopidogrel in Patients Treated With Omeprazole, Pantoprazole, or Famotidine |
- Platelet function as assessed by a CPA system [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 50 |
| Study Start Date: | September 2009 |
| Estimated Study Completion Date: | December 2011 |
| Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: PPI Platelet Inhibitory
Each patient will undergo 3 phases of drug therapy: A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily). At the end of each phase- each patient will undergo the following evaluation: Platelet reactivity |
Drug: PPI Platelet Inhibitory
Each patient will undergo 3 phases of drug therapy: A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily). At the end of each phase- each patient will undergo the following evaluation: Platelet reactivity Other Names:
|
Detailed Description:
In this study we will compare 3 different anti-acids regimens and their effect on platelet function
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject is at least 18 years old.
- Subject is willing to comply with pre-specified follow-up evaluation and can be contacted by telephone.
- Use of Clopidogrel (>=75mg) and Aspirin(>=75mg) for at least 1 month.
Exclusion Criteria:
- Known allergy to PPI of H2 blockers
- Known thrombocytopenia or thrombocytopathia
- Subject is currently enrolled in another investigational study of a new drug, biologic or device at the time of study screening. NOTE: Subjects who are participating in the long term follow-up phase of a previously investigational and now FDA-approved product are not excluded by this criterion.
- Subject with symptomatic heart failure of LVEF ≤ 25%
- Acute myocardial infarction within the past 30 days.
- No acute inflammatory event during the past month (e.g. infection, autoimmune or acute coronary event)
- Concurrent medical condition with a life expectancy of less than 12 months.
- Known severe renal failure (serum creatinine level >2.5 mg/dl).
- History of bleeding diathesis or coagulopathy or inability or unwillingness to receive blood transfusions.
- Evidence of active gastrointestinal bleeding or a history of such bleeding that is not known to have been treated and proven to have resolved.
- History of hepatitis (viral, ischemic or chemically-induced); clinical jaundice, history of cirrhosis.
- Patient treated with anticoagulant medication (Coumadin, LMWH)
Contacts and Locations| Israel | |
| Tel Aviv Medical Center | Not yet recruiting |
| Tel Aviv, Israel | |
| Contact: Shmuel Banai, MD 972-3-6973395 shmuelb@tasmc.health.gov.il | |
| Contact: Yaron Arbel, MD 972-3-6973313 yaronarbel@gmail.com | |
| Principal Investigator: Yaron Arbel, MD | |
| Study Chair: | Shmuel Banai, MD | Tel Aviv Medical Center, Israel |
More Information
No publications provided
| Responsible Party: | Prof. Shmuel Banai, Tel Aviv medical center |
| ClinicalTrials.gov Identifier: | NCT00950339 History of Changes |
| Other Study ID Numbers: | TASMC-09-SB-0196-09-TLV-CTIL |
| Study First Received: | April 19, 2009 |
| Last Updated: | July 30, 2009 |
| Health Authority: | Israel: Ethics Commission |
Keywords provided by Tel-Aviv Sourasky Medical Center:
|
GI bleeding clopidogrel aspirin prevention angiography |
Additional relevant MeSH terms:
|
Coronary Artery Disease Myocardial Ischemia Coronary Disease Gastrointestinal Hemorrhage Heart Diseases Hemorrhage Cardiovascular Diseases Arteriosclerosis Arterial Occlusive Diseases Vascular Diseases Gastrointestinal Diseases Digestive System Diseases Pathologic Processes Famotidine Omeprazole |
Pantoprazole Clopidogrel Anti-Ulcer Agents Gastrointestinal Agents Therapeutic Uses Pharmacologic Actions Histamine H2 Antagonists Histamine Antagonists Histamine Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Enzyme Inhibitors Platelet Aggregation Inhibitors Hematologic Agents |
ClinicalTrials.gov processed this record on June 13, 2013